News | Heart Failure | January 10, 2017

BioVentrix Announces First Revivent TC Transcatheter Ventricular Enhancement Procedure in Germany

Procedure achieved 24 percent left ventricular volume reduction in ischemic heart failure patient

BioVentrix, Revivent TC Transcatheter Ventricular Enhancement System, LIVE procedure, first in Germany

January 10, 2017 — BioVentrix Inc. announced in December the first closed-chest Revivent TC TransCatheter Ventricular Enhancement System procedure in Germany since receiving CE mark certification. The Less Invasive Ventricular Enhancement (LIVE) procedure was performed by interventional cardiologists Christian Frerker, M.D. and Tobias Schmidt, M.D., and by cardiothoracic surgeon Ralf Bader, M.D., at Asklepios Klinik St. Georg in Hamburg, Germany.  The St. Georg Heart team is led by Prof. Dr. Karl-Heinz Kuck, who is also the chairman of the Department of Cardiology and Electrophysiology.

The physicians implanted two anchor pairs and achieved a left ventricular volume reduction of 24 percent, which is a significant improvement for a patient suffering from ischemic heart failure.  Left ventricular volume reduction is a common measure of cardiac performance that significantly impacts the short and long-term survival rates. By remodeling the LV to a more normal shape and size, the implant improves pumping efficiency, decreases wall stress and immediately reverses patient symptoms.

"We are pleased to be the first center in Germany to perform the Revivent TC procedure after CE mark certification," said Frerker.  "The Revivent TC procedure continues to show significant clinical benefits to patients who suffer from ischemic cardiomyopathy post-myocardial infarction. It's a viable solution when guideline directed medical therapy (GDMT) is not suitable," he continued.

"The 24 percent volume reduction should directly impact the heart's pumping efficiency, which is a positive outcome for ischemic patients. That will result in an improvement in the patient's quality of life," added Schmidt.  "This is the only minimally invasive technology which enables plication of scar tissue resulting in complete exclusion outside the LV cavity," he continued.

"The Revivent TC procedure alleviates wall stress by the reshaping of the left ventricle and allowing for the heart to operate as it was intended to going forward.  The immediate impact the Revivent TC procedure has on a patient is life-changing," added Bader.

For more information: www.bioventrix.com

Related Content

Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
Overlay Init